ARTICLE | Emerging Company Profile

Prime Medicine: adding versatility to gene editing

Emerging Company Profile: David Liu’s latest gene editing play is developing a next-generation platform to rewrite DNA

July 13, 2021 11:03 AM UTC

CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind.

Prime Medicine Inc. launched on Tuesday with $315 million in funding and a CRISPR-based technology that adds flexibility and potential safety benefits over other gene editing tools...